Boys and young adult male patients with congenital adrenal hyperplasia receiving glucocorticoid treatment have lower bone ...

On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...

Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and ...

For the first time ever, the FDA has approved a treatment specifically for people with classic congenital adrenal hyperplasia (CAH), a genetic condition that affects the adrenal glands.

The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

PRESS RELEASEOMass Therapeutics appoints Birgitte Volck as Non-Executive DirectorOxford, United Kingdom – 26 February 2025 – ...

HBM Alpha Therapeutics has signed a collaboration and licensing agreement, granting an unnamed business partner exclusive ...

Signs a strategic collaboration and license agreement to advance novel therapies targeting corticotropin-releasing hormone ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...